# Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05533697/  
OnCo record `nct05533697` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Ipilimumab and Nivolumab in advanced solid tumours, run by ModernaTX, Inc., now recruiting.

## Summary

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05533697 by ModernaTX, Inc., with 361 participants planned, started 2022-09-01 and due to reach its primary completion in 2032-02-18. Interventions recorded: mRNA-4359, Pembrolizumab, Ipilimumab and Nivolumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05533697
- Phase: 1/2
- Setting: Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
- Sponsor: ModernaTX, Inc.
- Enrolled: 361

## Sources

- ClinicalTrials.gov NCT05533697: https://clinicaltrials.gov/study/NCT05533697

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05533697.json